GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Selling, General, & Admin. Expense

Alphamab Oncology (HKSE:09966) Selling, General, & Admin. Expense : HK$80.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Alphamab Oncology's selling, general, & admin. expense for the six months ended in Dec. 2024 was HK$42.7 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2024 was HK$80.0 Mil.


Alphamab Oncology Selling, General, & Admin. Expense Historical Data

The historical data trend for Alphamab Oncology's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Selling, General, & Admin. Expense Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 92.71 94.59 96.90 86.78 79.66

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.66 36.36 50.42 37.29 42.68

Competitive Comparison of Alphamab Oncology's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Alphamab Oncology's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alphamab Oncology's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Selling, General, & Admin. Expense falls into.


;
;

Alphamab Oncology Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$80.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alphamab Oncology  (HKSE:09966) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Alphamab Oncology Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphamab Oncology Business Description

Industry
Traded in Other Exchanges
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its products pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.
Executives
South Dakota Trust Company Llc 2301 Trustee
Xu Ting 2305 Beneficiary of a trust
Liu Yang 2307 Founder of a discretionary trust who can infl
Rubymab Ltd. 2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology Headlines

No Headlines